登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>VEGF R2 >KDR-H82E5

Biotinylated Human VEGF R2 / KDR Protein, Avitag™,His Tag

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

KDR,CD309,FLK1,VEGFR,VEGFR2

表达区间及表达系统(Source)

Biotinylated Human VEGF R2, Avitag,His Tag (KDR-H82E5) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823).

Predicted N-terminus: Ala 20

Request for sequence

蛋白结构(Molecular Characterization)

VEGF R2 Structure

This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.

The protein has a calculated MW of 85.9 kDa. The protein migrates as 120-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

VEGF R2 SDS-PAGE

Biotinylated Human VEGF R2, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

VEGF R2 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (QC tested).

Protocol

VEGF R2 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

VEGF R2 BLI

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

活性(Bioactivity)-FACS

VEGF R2 FACS

2e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No.KDR-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

Protocol

 

背景(Background)

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
VEGF R2靶点信息
英文全称:Vascular endothelial growth factor receptor 2
中文全称:血管内皮细胞生长因子受体2
种类:Homo sapiens
上市药物数量:17详情
临床药物数量:55详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定